Join Us | Contact Us | Sitemap | Korean

      About Us | Report | Custom Research | Support


Login

Category

Telecom/Wireless

Electronic

Digital Devices/Media/Broadcasting

Information Technology

Energy

Life Science

Chemical/Advanced Materials

Automotive

Environment

Consumer Goods

Marketing/Advertising

Finance

Construction

Transportation

Consumer Survey

Defence/Aerospace

Food/Beverage

Heavy Industry

Education

Industrial Machinery

International Trades

Sports/Leisure

Marine/Ship Building

Fashion

Government/Policy

Industrial Arts/Jewellery

Company Profiles

ETC

 
Location : HOME > Report > Life Science > Pharmaceuticals
The World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)
Publisher Kalorama Information
Date 2008-08
Quantity 125 pages
Type Report
Price

Print

Alzheimer¡¯s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study.

This report includes incidence of Alzheimer¡¯s disease worldwide with information for specific geographical regions; world demographics; life expectancy by country, and other general issues affecting the market.

Information is presented as a worldwide overview, with special emphasis on the U.S., Japan, Germany, and other key markets.

A market summary includes market analysis by products on the market and in development, in addition to a a regional market analysis, including:

  • US
  • Europe
  • Japan
  • Rest of World
as well as a competitive analysis of leading providers. Additionally key company profiles are included, with profiles of the following companies competing in this therapeutic area:
  • Eisai Co., Ltd.
  • Forest Laboratories
  • H. Lundbeck A/S
  • Johnson & Johnson
  • Merz Pharma GmbH
  • Novartis AG
  • Pfizer, Inc.
Markets are broken out by drug type:
  • Cholinesterase inhibitors
  • NMDA antagonists
as well as by product.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 50 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.


About Us | Privacy Polocy | Terms & Conditions | Delivery/Payment

Samwon Bldg., 210-1 Nonhyun-dong, Gangnam-gu, 135-996, Seoul, Korea | LNH, Inc.
Tel : 82-2-554-0001 / Fax : 82-2-3444-5501 / E-mail : sales@landh.co.kr
Copyright ¨Ï 2008 LNH, Inc. All rights reserved.